From: Reuters
Published March 10, 2008 11:29 AM

FDA postpones Schering panel for melanoma

WASHINGTON (Reuters) - A U.S. Food and Drug Administration advisory panel to review the use of Schering-Plough Corp's Pegintron drug to treat serious skin cancer has been postponed, the company said on Monday.

A group of FDA advisors had been expected to meet on Wednesday to review expanded use of the widely-used hepatitis C drug against melanoma, the deadliest skin cancer.

A Schering-Plough spokeswoman said the FDA was seeking clarification of existing data and no new date had been set.

(Reporting by Kim Dixon, editing by Gerald E. McCormick)

ADVERTISEMENT

Terms of Use | Privacy Policy

2014©. Copyright Environmental News Network